{"title":"Characterization and Antimicrobial Efficacy of a Bacteriophage Targeting Multidrug-Resistant <i><i>Escherichia coli</i></i>.","authors":"Tianshi Xiao, Chan Wang, Longbo Wang, Lingxian Xiang, Lin Li, Shaoqi Qu","doi":"10.1021/acsinfecdis.5c00651","DOIUrl":null,"url":null,"abstract":"<p><p>The emergence of multidrug-resistant (MDR) <i>Escherichia coli</i> poses a significant threat to global public health, necessitating alternative therapeutic strategies. In this study, we isolated and characterized a novel lytic bacteriophage (phage), vB_EcoM_51, from poultry farm sewage and evaluated its potential against MDR <i>E. coli</i>. Transmission electron microscopy revealed that the phage exhibits morphological features typical of the <i>Myoviridae</i> family, including a polyhedral head (∼66.62 nm) and a contractile tail (∼97.32 nm). Genome analysis indicated a double-stranded DNA virus of 167,016 bp with a GC content of 35.54%, classifying it within the <i>Tequatrovirus</i> genus. The phage showed potent lytic activity against eight <i>E. coli</i> strains and one <i>Salmonella enterica</i> strain. Stability assessments revealed broad thermal tolerance (-20 to 50 °C) and broad pH stability (pH 2-11). One-step growth kinetics analysis indicated rapid replication, with a latent period of 5 min and a burst size of approximately 212 plaque-forming units (PFU) per infected cell. In a mouse model infected with <i>E. coli</i>, phage treatment at 1 × 10<sup>9</sup> PFU significantly improved survival rates, reduced bacterial loads in organs, and attenuated inflammatory responses. Collectively, these findings demonstrate that phage vB_EcoM_51 represents a promising candidate for phage therapy against MDR infections.</p>","PeriodicalId":17,"journal":{"name":"ACS Infectious Diseases","volume":" ","pages":""},"PeriodicalIF":3.8000,"publicationDate":"2025-09-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"ACS Infectious Diseases","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1021/acsinfecdis.5c00651","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"CHEMISTRY, MEDICINAL","Score":null,"Total":0}
引用次数: 0
Abstract
The emergence of multidrug-resistant (MDR) Escherichia coli poses a significant threat to global public health, necessitating alternative therapeutic strategies. In this study, we isolated and characterized a novel lytic bacteriophage (phage), vB_EcoM_51, from poultry farm sewage and evaluated its potential against MDR E. coli. Transmission electron microscopy revealed that the phage exhibits morphological features typical of the Myoviridae family, including a polyhedral head (∼66.62 nm) and a contractile tail (∼97.32 nm). Genome analysis indicated a double-stranded DNA virus of 167,016 bp with a GC content of 35.54%, classifying it within the Tequatrovirus genus. The phage showed potent lytic activity against eight E. coli strains and one Salmonella enterica strain. Stability assessments revealed broad thermal tolerance (-20 to 50 °C) and broad pH stability (pH 2-11). One-step growth kinetics analysis indicated rapid replication, with a latent period of 5 min and a burst size of approximately 212 plaque-forming units (PFU) per infected cell. In a mouse model infected with E. coli, phage treatment at 1 × 109 PFU significantly improved survival rates, reduced bacterial loads in organs, and attenuated inflammatory responses. Collectively, these findings demonstrate that phage vB_EcoM_51 represents a promising candidate for phage therapy against MDR infections.
期刊介绍:
ACS Infectious Diseases will be the first journal to highlight chemistry and its role in this multidisciplinary and collaborative research area. The journal will cover a diverse array of topics including, but not limited to:
* Discovery and development of new antimicrobial agents — identified through target- or phenotypic-based approaches as well as compounds that induce synergy with antimicrobials.
* Characterization and validation of drug target or pathways — use of single target and genome-wide knockdown and knockouts, biochemical studies, structural biology, new technologies to facilitate characterization and prioritization of potential drug targets.
* Mechanism of drug resistance — fundamental research that advances our understanding of resistance; strategies to prevent resistance.
* Mechanisms of action — use of genetic, metabolomic, and activity- and affinity-based protein profiling to elucidate the mechanism of action of clinical and experimental antimicrobial agents.
* Host-pathogen interactions — tools for studying host-pathogen interactions, cellular biochemistry of hosts and pathogens, and molecular interactions of pathogens with host microbiota.
* Small molecule vaccine adjuvants for infectious disease.
* Viral and bacterial biochemistry and molecular biology.